Pharmaceutical statisticians propose strategic changes to enhance precision medicine's effectiveness, suggesting implications for broader applications.
Ten years after the launch of the Precision Medicine Initiative, its broader impact remains uncertain beyond select genetic and oncological cases. Here, we share our perspective as pharmaceutical statisticians and propose strategic shifts to realize its full potential. Desachy et al. share their perspectives as pharmaceutical statisticians on precision medicine. They find its broader impact uncertain despite select successes, and propose strategic shifts to realize its full potential.
No takes yet. Share an insight, caveat, or question.
Desachy et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: